BRINEURA
Biological
BioMarin Pharmaceutical Inc.
Total Payments
$267,269
Transactions
100
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $267,269 | 100 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $267,269 | 100 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Cerliponase alfa Observational Study (US) | BioMarin Pharmaceutical Inc. | $104,458 | 0 |
| Longitudinal Assessment of Atypical TPP1 Enzyme Deficiency Patients | BioMarin Pharmaceutical Inc. | $48,147 | 0 |
| BMN 111-902 | BioMarin Pharmaceutical Inc. | $37,405 | 0 |
| Phase 3 substudy enrolling approximately 100 subjects aged 18 to 70 years old with PKU who are concurrently participating in the 165-302 study | BioMarin Pharmaceutical Inc. | $37,227 | 0 |
| Examining Developmental Outcomes of Children Diagnosed with CLN2 Disease | BioMarin Pharmaceutical Inc. | $24,186 | 0 |
| Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A (GENEr8-3) | BioMarin Pharmaceutical Inc. | $8,733 | 0 |
| Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients | BioMarin Pharmaceutical Inc. | $7,114 | 0 |
Top Doctors Receiving Payments for BRINEURA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orlando, FL | $267,269 | 100 |
Ad
Manufacturing Companies
- BioMarin Pharmaceutical Inc. $267,269
Product Information
- Type Biological
- Total Payments $267,269
- Total Doctors 0
- Transactions 100
About BRINEURA
BRINEURA is a biological associated with $267,269 in payments to 0 healthcare providers, recorded across 100 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2024 to 2024. In 2024, $267,269 was paid across 100 transactions to 0 doctors.
The most common payment nature for BRINEURA is "Unspecified" ($267,269, 100.0% of total).
BRINEURA is associated with 7 research studies, including "Cerliponase alfa Observational Study (US)" ($104,458).